|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Calithera Biosciences, Inc. (CALA) |
|
|
$0.02 0.00 (0.00%) as of 4:30 Wed 4/24
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
97,237,000 |
| Market
Cap: |
1.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.015 - $0.365 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Calithera Biosciences is a clinical-stage precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Co.'s product candidate, CB-280, is an oral inhibitor of arginase, developed for the treatment of cystic fibrosis. Co. has also identified CB-668, an orally administered inhibitor of the immune-suppressive enzyme IL4I1. An additional arginase inhibitor, INCB001158, was discovered by Co. and is being developed by Incyte Corporation for oncology and hematology indications. Co. has developed CB-708, a selective, orally-bioavailable small molecule inhibitor of CD73.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
121,333 |
| Total Sell Value |
$0 |
$0 |
$0 |
$46,810 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pakianathan Deepika |
Director |
– • – |
2023-01-27 |
4 |
S |
$0.39 |
$46,810 |
I/I |
(121,333) |
0 |
|
9% |
|
| Molineaux Susan |
PRESIDENT & CEO |
• • – |
2023-01-23 |
4 |
D |
$0.45 |
$235 |
I/I |
(526) |
27,859 |
|
- |
|
| Molineaux Christopher |
SR. VP, DEVELOPMENT |
• – – |
2023-01-23 |
4 |
D |
$0.45 |
$97 |
I/I |
(217) |
27,859 |
|
- |
|
| Wong Stephanie |
See Remarks |
• – – |
2023-01-23 |
4 |
D |
$0.45 |
$141 |
D/D |
(317) |
6,287 |
|
- |
|
| Kuriakose Emil |
CHIEF MEDICAL OFFICER |
• – – |
2023-01-23 |
4 |
D |
$0.45 |
$35 |
D/D |
(79) |
3,539 |
|
- |
|
| Sjogren Eric |
SR. VP, DRUG DISCOVERY |
• – – |
2023-01-23 |
4 |
D |
$0.45 |
$124 |
D/D |
(279) |
8,467 |
|
- |
|
| Kuriakose Emil |
CHIEF MEDICAL OFFICER |
• – – |
2022-01-21 |
4 |
D |
$0.49 |
$327 |
D/D |
(666) |
67,369 |
|
- |
|
| Sjogren Eric |
SR. VP, DRUG DISCOVERY |
• – – |
2022-01-21 |
4 |
D |
$0.49 |
$2,356 |
D/D |
(4,794) |
172,434 |
|
- |
|
| Wong Stephanie |
See Remarks |
• – – |
2022-01-21 |
4 |
D |
$0.49 |
$2,746 |
D/D |
(5,586) |
132,085 |
|
- |
|
| Parlati Francesco |
SR. VP, RESEARCH |
• – – |
2022-01-21 |
4 |
D |
$0.49 |
$2,356 |
D/D |
(4,794) |
140,998 |
|
- |
|
| Wong Stephanie |
See Remarks |
• – – |
2022-01-04 |
4 |
D |
$0.66 |
$11,938 |
D/D |
(18,077) |
137,671 |
|
- |
|
| Parlati Francesco |
SR. VP, RESEARCH |
• – – |
2022-01-04 |
4 |
D |
$0.66 |
$11,938 |
D/D |
(18,077) |
145,792 |
|
- |
|
| Kuriakose Emil |
CHIEF MEDICAL OFFICER |
• – – |
2022-01-04 |
4 |
D |
$0.66 |
$2,546 |
D/D |
(3,855) |
68,035 |
|
- |
|
| Sjogren Eric |
SR. VP, DRUG DISCOVERY |
• – – |
2022-01-04 |
4 |
D |
$0.66 |
$11,938 |
D/D |
(18,077) |
177,228 |
|
- |
|
| Orford Keith |
Director |
• – – |
2021-11-11 |
4 |
S |
$0.88 |
$42,407 |
D/D |
(48,190) |
66,094 |
|
39% |
|
| Orford Keith |
Director |
• – – |
2021-11-10 |
4 |
S |
$0.86 |
$25,695 |
D/D |
(30,000) |
114,284 |
|
38% |
|
| Molineaux Susan |
PRESIDENT & CEO |
• • – |
2021-11-10 |
4 |
B |
$0.85 |
$84,670 |
I/I |
100,000 |
557,188 |
2.66 |
-38% |
|
| Drachman Jonathan G |
Director |
– • – |
2021-11-10 |
4 |
B |
$0.86 |
$171,900 |
D/D |
200,000 |
200,000 |
2.39 |
-38% |
|
| Molineaux Christopher |
SR. VP, DEVELOPMENT |
• – – |
2021-11-10 |
4 |
B |
$0.85 |
$84,670 |
I/I |
100,000 |
557,188 |
1.99 |
-38% |
|
| Orford Keith |
Director |
– • – |
2021-11-09 |
4 |
S |
$0.84 |
$43,520 |
D/D |
(51,810) |
144,284 |
|
35% |
|
| Kuriakose Emil |
CHIEF MEDICAL OFFICER |
• – – |
2021-11-08 |
4 |
D |
$0.87 |
$2,677 |
D/D |
(3,077) |
69,390 |
|
- |
|
| Wong Stephanie |
See Remarks |
• – – |
2021-11-08 |
4 |
D |
$0.87 |
$13,542 |
D/D |
(15,566) |
155,748 |
|
- |
|
| Sjogren Eric |
SR. VP, DRUG DISCOVERY |
• – – |
2021-11-08 |
4 |
D |
$0.87 |
$13,542 |
D/D |
(15,566) |
195,305 |
|
- |
|
| Parlati Francesco |
SR. VP, RESEARCH |
• – – |
2021-11-08 |
4 |
D |
$0.87 |
$13,542 |
D/D |
(15,566) |
163,869 |
|
- |
|
| Kuriakose Emil |
CHIEF MEDICAL OFFICEROfficer |
• – – |
2021-11-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
60,467 |
|
-35% |
|
141 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
